Upregulation of human leukocyte antigen–G expression and its clinical significance in ductal breast cancer

Chen, Haixiao; Lin, Aifen; Shen, Chaojun; Zhen, Rui; Chen, Baoguo; Zhang, Xia; Cao, Fei-Ling; Zhang, Jiangang; Yan, Wei‐Hua

doi:10.1016/j.humimm.2010.06.009

Cited by 67 publications

(52 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibodies applied for probing HLA-G expression in that study were not clearly described by EI-Chennawi et al and the positive and negative controls to guarantee the HLA-G detection was not included. Unlike other malignancies, such as lung cancer and hepatocellular carcinoma, HLA-G expression in bladder TCC is unrelated to disease stage [30,34,39,40]; furthermore, no significant difference in sHLA-G levels was observed between the TCC bladder cancer patients and normal controls in our study, whereas elevations of sHLA-G expression was found in patients with various other cancers [34,[45][46][47], raising the hypothesis that the clinical relevance of HLA-G is tumor type dependent and varies among different types of malignancies.…”

Section: Discussioncontrasting

confidence: 63%

Tumor-specific upregulation of human leukocyte antigen–G expression in bladder transitional cell carcinoma

Ling-hong

Huang²,

Zhang³

et al. 2010

Human Immunology

Self Cite

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 63%

Tumor-specific upregulation of human leukocyte antigen–G expression in bladder transitional cell carcinoma

Ling-hong

Huang²,

Zhang³

et al. 2010

Human Immunology

Self Cite

View full text Add to dashboard Cite

“…In an initial study, Singer et al 45 reported that sHLA-G levels were significantly higher in malignant ovarian and breast carcinoma ascites than that in the benign controls, and receiver-operating characteristic curve (ROC) analysis showed that the area under curve for sHLA-G was 0.95 for malignant versus benign ascites specimens. Significantly enhanced sHLA-G levels in patients with other cancers was reported in later studies and proven to be useful in assisting the diagnosis of 47 and 0.84 in distinguishing colorectal cancer from benign colorectal diseases, respectively. 48 In our study, sHLA-G levels in plasma were significantly increased in ESCC patients compared to that in normal controls, and the area under ROC for sHLA-G levels between the patients and normal controls was 0.992.…”

Section: Tumor Immunologymentioning

confidence: 76%

Human leukocyte antigen‐G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma

Lin

Zhang

Zhou

et al. 2011

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Human leukocyte antigen (HLA)‐G inhibits functions of immune component cells and promotes malignant cells evading from antitumor immunity. We investigated the clinical relevance of HLA‐G expression in esophageal squamous cell carcinoma (ESCC). In our study, HLA‐G expression in 79 primary ESCC lesions and corresponding adjacent normal tissues were analyzed with immunohistochemistry. Soluble HLA‐G (sHLA‐G) in plasma was detected with enzyme‐linked immunosorbent assay (ELISA) in 41 ESCC patients (including 19 case‐matched lesions and plasma samples) and in 153 normal healthy controls. HLA‐G expression was observed in 65.8% (52/79) of the ESCC lesions but not in adjacent normal esophageal tissues. HLA‐G expression was more frequently observed in patients with advanced disease stage (III/IV vs. I/II, p = 0.01). Patients with HLA‐G expression had a significantly worse survival, and HLA‐G could be an independent prognostic factor. sHLA‐G levels in plasma were significantly increased in patients compared to normal controls (median: 152.4 U/ml vs. 8.9 U/ml, p < 0.001). The area under receiver‐operating characteristic (ROC) curve for sHLA‐G in plasma was 0.992. However, no significant correlation was found between sHLA‐G in plasma and clinical parameters studied. In conclusion, our findings indicated that HLA‐G expression in ESCC is associated with poor survival and could be a prognostic indicator. Furthermore, increased levels of sHLA‐G in plasma might be a useful preoperative biomarker for diagnosis.

show abstract

“…Among these studies, there is a high frequency of tumor cell-surface HLA-G expression with an absence in healthy tissue, and increased sHLA-G levels has been detected in various body fluids in a variety of cancers (14). Expression of HLA-G was found to be correlated with clinical parameters such as more advanced disease stage, tumor metastasis and/or with a worse prognosis in tumor patients, indicating that HLA-G could facilitate tumor immune escape, invasiveness and metastasis; thereby HLA-G expression was found to be associated with advanced clinical stage and disease progression and HLA-G expression was also documented as an unfavorable prognostic factor for many kinds of solid malignancies, including breast cancer (59)(60)(61)(62)(63)(64), colorectal cancer (65,66), cervical cancer (67,68), endometrial of allogeneic skin graft survival (52). In an immunocompetent HLA-G1 + M8…”

Section: Relevance Of Hla-g Expression In Cancersmentioning

confidence: 99%

Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy

Lin

Yan

2015

Mol Med

Self Cite

110

View full text Add to dashboard Cite

Aberrant induction of human leukocyte antigen-G (HLA-G) expression has been observed in various malignancies and is strongly associated with tumor immune escape, metastasis and poor prognosis. To date, great achievements have been made in understanding the underlying mechanisms of HLA-G involved in tumor progression. HLA-G could lead to tumor evasion by inhibition of immune cell cytolysis, differentiation and proliferation and inhibition of cytokine production, induction of immune cell apoptosis, generation of regulatory cells and expansion of myeloid-derived suppressive cells and by impairment of chemotaxis. Moreover, HLA-G could arm tumor cells with a higher invasive and metastatic potential with the upregulation of tumor-promoting factor expression such as matrix metalloproteinases (MMPs), indicating that ectopic HLA-G expression could render multiple effects during the progression of malignancies. In this review, we summarized the mechanisms of HLA-G involved in promoting tumor cell immune escaping, metastasis and disease progression. Special attention will be paid to its significance as an attractive therapeutic target in cancers.

show abstract

Upregulation of human leukocyte antigen–G expression and its clinical significance in ductal breast cancer

Cited by 67 publications

References 37 publications

Tumor-specific upregulation of human leukocyte antigen–G expression in bladder transitional cell carcinoma

Tumor-specific upregulation of human leukocyte antigen–G expression in bladder transitional cell carcinoma

Human leukocyte antigen‐G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma

Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy

Contact Info

Product

Resources

About